Turnstone Biologics raises $80m in Series D financing
Turnstone Biologics, a clinical-stage biotechnology company focused on developing cancer immunotherapies, has raised $80 million in Series D financing.
Turnstone Biologics, a clinical-stage biotechnology company focused on developing cancer immunotherapies, has raised $80 million in Series D financing.
Copyright PEI Media
Not for publication, email or dissemination
